Amplified HER2 (aHER2) is invariably lost regardless of the clinical setting (early or metastatic disease) and testing method, e.g. whether assessed on tumor tissue DNA (tDNA) [2–4] or circulating cell-free DNA (cfDNA) [5–8]. This evidence concerns the gene ERBB2 and neoplasm.